A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Incyte (INCY – Research Report), with a price target of $77.00. The company’s shares closed last ...

In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other AI updates worth taking a look at. In a Bloomberg interview, SandboxAQ CEO Jack Hidary ...

In the preceding three months, 6 analysts have released ratings for Incyte INCY, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...

In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with ...

Bank of New York Mellon Corp boosted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 7.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Citi keeps a Buy rating on Incyte (INCY) with an $88 price target after the company presented data from its pivotal Phase 3 TRuE-PN1 trial studying Opzelura cream in prurigo nodularis. The study ...